Tacrolimus - VIVUS

Drug Profile

Tacrolimus - VIVUS

Alternative Names: SPI-026

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selten Pharma; Stanford University
  • Developer VIVUS
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 02 Nov 2017 VIVUS announces intention to submit IND to US FDA for Pulmonary arterial hypertension in the first half of 2018
  • 22 Sep 2017 Tacrolimus is still in clinical development for Pulmonary arterial hypertension in USA (Vivus annual report, Form 10-k,
  • 06 Sep 2017 Tacrolimus - Selten Pharma receives Orphan Drug status for Pulmonary arterial hypertension in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top